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The hormone thyroxine that regulates mammalian metabolism is carried
and stored in the blood by thyroxine-binding globulin (TBG). We demon-
strate here that the release of thyroxine from TBG occurs by a
temperature-sensitive mechanism and show how this will provide a homo-
eostatic adjustment of the concentration of thyroxine to match metabolic
needs, as with the hypothermia and torpor of small animals. In humans, a
rise in temperature, as in infections, will trigger an accelerated release of
thyroxine, resulting in a predictable 23% increase in the concentration of
free thyroxine at 398C. The in vivo relevance of this fever-response is affirmed
in an environmental adaptation in aboriginal Australians. We show how two
mutations incorporated in their TBG interact in a way that will halve the
surge in thyroxine release, and hence the boost in metabolic rate that
would otherwise occur as body temperatures exceed 378C. The overall find-
ings open insights into physiological changes that accompany variations in
body temperature, as notably in fevers.1. Introduction
Thyroxine is the hormone that most directly controls mammalian activity,
with its immediate derivatives regulating cellular oxygen consumption and
the metabolism of body and brain [1]. Consequently, tissue concentrations of
thyroxine are precisely defined: too much leads to hyperactivity and too little
to dormancy. The storage and transport of thyroxine in blood has been well
documented in humans [2,3]. The steady-state concentration of thyroxine in
blood is set centrally by the secretion of thyroid stimulating hormone (TSH)
but the maintenance of this concentration throughout the tissues is owing to
the equilibrated release of thyroxine from its carrier protein in the blood,
thyroxine-binding globulin (TBG) [2–4]. The binding affinity of TBG for thyrox-
ine is exceptionally tight such that in humans only 0.03% of the total blood
thyroxine is in the free form, at picomolar concentration. Other thyroxine
carriers in blood, albumin and transthyretin, contribute to the equilibration of
plasma concentrations but their influence is minor [5]. The overwhelming pro-
portion of the circulating thyroxine is bound as a ligand to TBG, which acts as
both a store and a buffer to give an equilibrated release of thyroxine to the
tissues. The binding capacity of circulating TBG is only partially saturated,
and it is the percentage saturation, 20% or more, that by the law of mass
action determines the concentration of free thyroxine in the tissues. Although
the steady-state concentration of free thyroxine and hence the percentage satur-
ation of TBG is determined centrally we demonstrate here, as we have similarly
shown with the closely related corticosteroid-binding globulin (CBG) [6,7], how
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Figure 1. Temperature-responsive release of thyroxine from TBG. (a) Thyroxine, in space-filling form. Movement of the reactive centre loop (yellow) into and out of
the A-sheet (red) of TBG directly affects the binding site magnified in (b) showing the interactions that stabilize thyroxine (skeletal form) in the binding site. Entry of
the reactive centre loop will cause a steric perturbation and the expansion of the A-sheet will displace the connecting loops (green) that surround the bound
thyroxine. The Australian mutations, A191T and L283F, flank the binding site. (c,d ) The proportional loss of hormone-binding affinity with increasing temperature
(Kd/Kd378C): (c) shown with the homologous CBG, from Chan [7] circles and Mickelson [14] crosses; (d ) with TBG and fluorophore– thyroxine data from table 1. The
plot of the L283F variant of TBG (interrupted line) is superimposable on that of the wild-type, including the inflection at 378C.
rspb.royalsocietypublishing.org
Proc.R.Soc.B
281:20132747
2the release of thyroxine from TBG is further adjusted within
the circulation by a temperature-sensitive modulation of its
binding affinity.
TBG and CBG are members of the serpin family of serine
protease inhibitors, with homologous hormone-binding sites.
Although both hormone carriers have lost any inhibitory
activity, they retain the ability to undergo the remarkable
conformational change, from a stressed to a relaxed form,
that characterizes the serpins [8,9]. Recent structure-based
studies [4,10–13] show how the initiating stage in this
change, the temperature-sensitive movement of the reactive
loop into and out of the main beta-sheet of the molecule,
affects the plasticity of the underlying hormone-binding
pocket (figure 1a,b). When the reactive loop is fully exposed,
as favoured at lower temperatures, the binding pocket readily
adopts an optimal conformation with a high binding affinity.
Conversely, the partial entry of the reactive loop into the
A-sheet as the temperature rises will perturb the bindingpocket with a resultant decrease in affinity and increased
release of the bound hormone.
The existence of this temperature-responsive mechanism
[15] is readily demonstrable with CBG [6,7], which has a mea-
surable change in fluorescence on release of its bound cortisol
(figure 1c). The assessment of changes in the affinity of TBG,
however, is more challenging, as it undergoes only minor
shifts in fluorescence, with the monitoring of its dissociation
rate being further complicated by its exceptionally strong
binding affinity (Kd 80 pM). To overcome this, we syn-
thesized [13] a fluorescent thyroxine-adduct that is
structurally identical to thyroxine in its binding to TBG but
does so with a much-decreased affinity.2. Material and methods
Wild-type recombinant human TBG and its engineered variants,
A191T, L283F and A191T/L283F and the fluorophore-adduct of
Table 1. Variation of TBG binding affinities and free-thyroxine concentrations with temperature. (a) Kd, and Kd/Kd378C ratios of recombinant TBG variants with
the thyroxine–fluorophore. Kd measurements were repeated more than three times in duplicate; data are means+ s.d. (b) The fluorophore Kd/Kd378C derived
changes in free thyroxine (FT4) with temperature (shown in bold) are in consistent agreement with previous independently derived values with thyroxine and
isolated plasma TBG [20] (non-bold), and the assay of free thyroxine in plasma at 218C and 378C, [19,20] (figure 2). Calculations based on FT4 of 20 pM and
TBG saturation of 20% at 378C.
(a) TBG: thyroxine–fluorophore binding affinity with temperature
TBG TBG-191 TBG-283 TBG-191–283
Temp (8C) Kd nM Kd/Kd378C Kd nM Kd/Kd378C Kd nM Kd/Kd378C Kd nM Kd/Kd378C
7 1.1+ 0.3 0.20 — — — — — —
22 2.2+ 0.2 0.40 3.7+ 0.3 0.47 2.4+ 0.3 0.43 3.1+ 0.3 0.45
37 5.6+ 0.1 1 7.8+ 0.3 1 5.6+ 0.2 1 6.9+ 0.5 1
39 6.9+ 0.5 1.23 8.6+ 0.4 1.10 6.9+ 0.3 1.23 7.7+ 0.2 1.12
42 7.5+ 0.3 1.34 9.5+ 0.3 1.21 7.5+ 0.4 1.34 8.6+ 0.2 1.24
(b) Free thyroxine (FT4) from fluorophore ratios and direct T4 Kd values
temperature (8C)
5 7 21 22 25 37 39 42
Kd/Kd378C (%) — 20 41
a 40 — — 100 123 133
Kd T4 (pM) 20
b — — — 40c 64b 75c, 110b — —
FT4 (pM) 3.6 4 8 8 11 12 20 25 27
aSerum FT4 218C/378C ratio, Ross & Benraad [19].
Kd T4:
bKorcek et al. [18], cQi et al. [13].
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3thyroxine (L-thyroxine-6-carboxyfluoroscein) were prepared
as previously described [4,13]. Binding affinities were deter-
mined by fluorescence titration in phosphate buffer pH 7.4
at defined temperatures as detailed in Qi et al. [13]. All Kd
measurements were carried out three times in duplicate. Ther-
mal stability of recombinant variants was determined by
ThermoFluor assay: samples were heated gradually to dena-
turation; the exposure of the hydrophobic core allowing the
dye, SYPRO Orange, to bind and fluoresce. Figure 1a,b was
prepared from our previously deposited coordinates as
detailed in Zhou et al. [12].
Thyroxine indices: free thyroxine and % saturation of TBG
and its variants over a range of temperatures were calculated
using a free-thyroxine concentration at 378C of 20 pM based,
with recent updating [16], on a plasma range of 12–26 pM.
The binding constant Kd of thyroxine with TBG at 378C and
pH 7.4 has been variously reported (bracketed, inverse Ka
10(10) M-1): in 1972 [17] as 60 pM (Ka 1.68), more definitively
with isolated TBG by Korcek & Tabachnik [18] in 1976 as 110 pM
(Ka 0.90), in plasma by Ross & Benraad [19] 1992 as 67 pM (Ka
1.5) and from our own competitive-assay with recombinant TBG
[13] as 75 pM (Ka 1.33). We have adopted here the mean of these
results, a Kd of 80 pM (Ka 1.25), but note that whatever affinity is
chosen will affect only the magnitude of derived values and not
the proportional changes central to this paper. With a Kd of
80 pM and a free thyroxine at 378C of 20 pM, the saturation of
TBG will be 20%.
Other proteins that bind thyroxine in the plasma do so with a
very much lower affinity than TBG. As Schreiber describes [5]
and others show experimentally [19,20], if the concentration of
free thyroxine is less than the Kd of TBG, as in plasma, the
changes in free thyroxine can be directly derived from the
changes in the Kd of TBG. This allows the calculation here ofthe concentration of free thyroxine [FT4] and the percentage
saturation of TBG, Y, from the law of mass action:
½FT4 ¼ YKdð1 YÞ and Y ¼
½FT4
ð½FT4 þ KdÞ :
3. Results and discussion
The thyroxine–fluorophore was used to determine the pro-
portional change in binding affinity, Kd/Kd378C that takes
place over a range of temperatures in human TBG and its
engineered variants (table 1b).
The use of the fluorophore–thyroxine Kd/Kd378C ratios
to calculate the proportional changes that will occur to the
binding affinity of thyroxine to TBG in plasma is validated
in table 1a and figure 2 by the agreement with values inde-
pendently determined with thyroxine [18] and with the
direct assays by others of free-thyroxine concentrations in
the blood at room and body temperature [19,20]. The plot
of Kd/Kd378C ratios versus temperature in figure 1d and of
consequent blood free-thyroxine concentrations (table 1b
and figure 2) demonstrate how changes in the binding affi-
nity of TBG provide an inherent adjustment of thyroxine
levels to match metabolic needs.
(a) Small mammals and hypothermia
Although our data here and almost all the detailed knowl-
edge of the physiology of thyroxine transport are derived
from the human, there is clear evidence that the system is
strongly conserved in all mammals. This is seen not only in
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Figure 2. Variation in free thyroxine with temperature from Kd/Kd378C ratios
(hatched bars), 20 pM at 378C rising to 25 pM at 398C with wt-TBG, but
dampened to 22 pM in the 191/283 TBG (Aus) variant (upper normal
limit, dashed line). The open (non-hatched) bars show values from indepen-
dent determinations by others using plasma-derived thyroxine [18] and direct
assays of plasma-free thyroxine [19,20]. The comparative bars are based on a
defined Kd of 80 pM, free thyroxine of 20 pM and a TBG saturation of 20%,
at 378C.
rspb.royalsocietypublishing.org
Proc.R.Soc.B
281:20132747
4the conservation of TBG sequence in diverse mammals [21]
but also in the identity of molecular mechanisms based on
crystal structures from the mouse [11] and the human
[12,13]. Hence, the findings here (figures 1d and 2) have
direct relevance to the hypothermia and torpor that occur
in small animals [22,23]. Based on a saturation of TBG in
the human of 20%, there will be a homoeostatic decrease in
the concentration of free thyroxine as body temperature
falls, with a fivefold drop from 20 pM at 378C to a baseline
4 pM at 78C. Similarly, as body temperature is restored, the
thyroxine, stably stored in the TBG, will be increasingly
released, rising to meet the needs of full activity at 378C.(b) Humans and fever
The critical metabolic demands of a much larger brain make
humans especially sensitive to changes in the release of thyr-
oxine and even mild hypothermia, if prolonged, is fatal. A
physiological change in body temperature does, however,
occur in humans with the fevers that are induced by inflam-
mation and infection. The accelerated decrease in binding
affinity that will accompany the increase in body temperature
from 378 to 398C and, exceptionally, to 428C is seen in
figure 1d. Evidence that this fever-induced decrease in bind-
ing affinity is specific and purposeful and comes from a
similar but even greater acceleration of hormone release in
the closely related CBG (figure 1c). The loss of affinity in
TBG at fever temperatures has, however, even more direct
physiological impact than that of CBG because of the much
tighter hormone-binding affinity of TBG and the precisely
defined limits of free-thyroxine concentration in the blood.
Any changes in the Kd of TBG will be directly reflected in
changes in free-thyroxine levels in the blood with a rise in
body temperature to 398C predictably giving a 23% increase
in concentration, temporarily moving into the range seen in
the clinical disorder of hyperthyroidism (figure 2).(c) Adaptation in the aboriginal Australian
The in vivo relevance of this surge in thyroxine release in
fevers is affirmed by what had been a perplexing finding,
the presence of two linked mutations in the TBG of aboriginal
Australians [24–26]. Surveys in West Australia had shown
the presence of this variant TBG in some 40% of the
aboriginal population in association with lowered levels of
total-thyroxine and total-TBG. The clue as to the functional
significance of the mutations, a replacement of alanine 191
by a threonine and of leucine 283 by a phenylalanine, came
from their placement on the periphery of the thyroxine-
binding site [4] (figure 1b). Alanine 191 is immediately
adjacent to the point of entry of the reactive loop into the
main beta-sheet of TBG and its replacement by a polar threo-
nine will predictably affect the H-bond network that links to
the bound thyroxine. The consequence of this replacement is
shown here with the change in thyroxine-binding affinity of
the recombinantly expressed Ala191Thr TBG. The replace-
ment critically results (figure 3a,b) in an abolition of the
accelerated release of thyroxine that takes place as the temp-
erature rises above 378C, with the 23% increase in free
thyroxine that would otherwise occur at 398C being reduced
by the mutation to a 10% increase.
An enigmatic accompanying finding strengthens the
deduction that the Ala191Thr mutation in aboriginal Austra-
lians is selectively advantageous. This is the presence of the
linked second mutation, with the replacement of the leucine
at 283 by a bulkier phenylalanine. The puzzle was that
this Leu283Phe mutation occurs not uncommonly in other
populations without any discernible functional consequen-
ces [26]. We confirm here (table 1 and figure 1d ) that this
variant does, by itself, precisely retain the affinity and temp-
erature response of the wild-type TBG. However, when the
Leu283Phe replacement is co-expressed with that of
Ala191Thr there is clearly an advantageous interaction. The
thyroxine affinity of the double mutant moves closer to the
physiological Kd at 378C, with little loss of the thermal pro-
tection provided by the Ala191Thr replacement. In doing
so, the linked mutation maintains the percentage saturation
of TBG closer to the norm. With just the single Ala191Thr
mutation, the saturation of TBG would need, by the law of
mass action, to decrease from 20 to 15% in order to provide
a physiological free thyroxine of 20 pM at 378C. But with
the addition of the second Leu283Phe mutation, this decrease
changes to a more adequate 17% saturation.
The findings fit well with the quantitation by Takamatsu
et al. in 1987 [27] of ancillary changes in an aboriginal
hemizygote for the A191T/L283F TBG, giving a TBG concen-
tration 74% of that of the normal and a much-reduced total
thyroxine at 58% of a normal pool. The decreased overall
level to 74% is in keeping with studies of other serpins,
which show that functional mutations consistently result in
a comparable decrease in the efficiency of expression. The
further reduction in the saturation of this diminished level
of TBG, as determined here with the recombinant variant
from 20 to 17% (figure 3b), would result in an overall
reduction in the total thyroxine to 62%, compatible with
the 58% observed in the 1987 study. Further support for the
relevance of the findings reported here with recombinant
TBG to those occurring in vivo [27] is provided by the identical
denaturation temperature of the recombinant double mutant
at 528C (figure 3c) to that measured in an earlier study of the
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Figure 3. Changed binding affinity of Australian variant TBG at raised body temperatures. (a) Modified response of the A191T variant (full line) and the double
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The identical change in the single A191 recombinant (grey) confirms that the instability is independent of the L283F mutation.
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5plasma variant [28] and, as in that study, being only slightly
decreased from the denaturation temperature of the
wild-type plasma TBG at 558C [8].
Thus, the paired polymorphisms provide the aboriginal
Australian with a TBG that maintains its properties as a storage
and carrier protein while having the additional local advantage
of providing a reduced metabolic response to increased body
temperatures. In a temperate climate, the boost to thyroxine
release and increased metabolism that accompanies the rise in
body temperatures in fevers will be an advantageous response
to infection. But the same accelerated increase in metabolism
could affect the survival of a population historically exposed
to the arid environment of central Australia, with ambient
temperatures of 458C or above. There the life threatening risk
is not so much the infection itself, but rather the dehydration
and heat exhaustion that accompany dysentery and other
common illnesses in infancy and childhood.(d) Wider implications
The recognition of this environmental adaptation in the abori-
ginal Australian has much wider significance in affirming the
physiological relevance of the temperature-regulated release of
thyroxine in blood. Although the central secretion of TSH con-
trols the concentration of thyroxine in the longer term, the
variations with temperature of free-thyroxine concentrations
in the circulation will be rapid and reversible. This temperature
responsive adjustment of the concentration of free thyroxine
has been largely overlooked in the past, as it had been
assumed that the thyroxine–TBG binding affinity remains
constant. Moreover, thyroxine assays have customarily beencarried out at room temperature. Measured retrospectively in
this way, blood samples taken in hypothermia, in heatstroke,
or from an infant with fever, will all be reported as having
an unchanged free thyroxine.
The demonstration that TBG, as with CBG [6,7], acts as a
protein thermocouple, has direct physiological implications.
Such temperature-sensitive regulation of hormone release
will affect everyday lives. For example, the accelerated release
that will take place as the body core temperature rises to 398C
in a hot-bath or sauna will contribute to an enhancement of
the metabolism of body and mind—euphoria and eureka!
A similar boost in hormone release also opens a contributory
explanation for the common occurrence of febrile convulsions
in infancy [29]. The brain is sensitive to changes in free thyr-
oxine and raised levels in thyrotoxicosis in adults can result
in convulsive seizures that cease, with no after-effects,
when the thyroxine level returns to normal [30,31]. Compar-
able seizures also commonly occur in infants in conjunction
with the spiking increases in temperature that accompany
incidental infections at that age. The surge in thyroxine
release that will occur in response to the increases in the
temperature of the brain in fevers [32] poses a potential
exacerbating factor in the childhood seizures—a conclusion
reinforced by the prompt cessation of the convulsions as
the infant’s body temperature is cooled.
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